NIMG-81. EFFECT OF RE-TREATMENT WITH TEMOZOLOMIDE IN GRADE 2/3 IDH MUTANT GLIOMAS AT FIRST PROGRESSION

作者
Lalanthica Yogendran,Salma Abbas,Zachary Scharf,Sohil Patel,David Schiff
出处
期刊:Neuro-oncology [Oxford University Press]
卷期号:24 (Supplement_7): vii183-vii184
标识
DOI:10.1093/neuonc/noac209.699
摘要

Abstract BACKGROUND Patients with WHO grade 2 and 3 IDHmt gliomas commonly receive temozolomide, with or without radiation therapy, as initial therapy. At progression, temozolomide is sometimes reinstated despite a paucity of data on effectiveness. METHODS We reviewed imaging outcomes of patients with grade 2/3 IDHmt gliomas re-treated with temozolomide at first progression between 2007 and 2019. RESULTS 15 subjects included six grade 2 and five grade 3 oligodendrogliomas, one grade 2 and three grade 3 astrocytomas. Median time between completion of first temozolomide course and initiation of re-treatment was 47 months (range, 8-126 months). Best treatment response after first progression by RANO criteria was stable disease in 10 and progressive disease in 5 patients. Median progression free survival with temozolomide re-treatment was 27.4 months (95% CI: [13.8, 41.2 months] and median overall survival 47.8 months (95% CI: [31.5, 125.6 months]). In 14 patients who had pre- and post- first tumor progression rate measurements, the mean rate of tumor growth by bidimensional product was 0.29 cm2/month (95% CI: [0.17, 0.42 cm2/month], p< 0.001) prior to first tumor progression versus 0.47 cm2/month (95 CI: [0.08, 0.85 cm2/month], p=0.021) during re-treatment with monotherapy temozolomide (prior vs after, p=0.371). The volumetric mean rate of tumor growth was 1.12 cc/month (95% CI: [0.31, 1.93 cc/month], p=0.010) prior to first tumor progression versus 1.29 cc/month (95% CI: [0.15, 2.43 cc/month], p=0.030) during temozolomide re-treatment (prior vs. after, p=0.802). CONCLUSION Among 15 patients with progressive IDHmt glioma re-treated with temozolomide, there was no radiographic response by RANO criteria nor a decrease in tumor growth rate during the re-treatment period compared to immediate pre-re-treatment period. These findings suggest previously treated, progressive IDHmt gliomas are generally resistant to temozolomide, underscoring the need for novel therapies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
汉堡包的应助被海阔天空采纳,获得10
1秒前
乐乐的应助被神棍喜来乐采纳,获得10
2秒前
2秒前
2秒前
2秒前
Ykaor发布了新的文献求助10
3秒前
3秒前
fmh发布了新的文献求助10
3秒前
Ava的应助被开心德地采纳,获得50
4秒前
CTA发布了新的文献求助10
5秒前
细腻山菡完成签到,获得积分20
6秒前
8秒前
orange发布了新的文献求助10
8秒前
mgqqlwq发布了新的文献求助10
9秒前
10秒前
11秒前
11秒前
11秒前
FashionBoy的应助被baijie采纳,获得10
11秒前
科研通AI6.2的应助被顺利焦采纳,获得10
11秒前
汉堡包的应助被wg采纳,获得10
12秒前
orange完成签到,获得积分10
12秒前
molihuakai的应助被搞怪的乐荷采纳,获得10
13秒前
香蕉觅云的应助被开心德地采纳,获得10
13秒前
开朗不凡发布了新的文献求助10
14秒前
迪丽热巴完成签到,获得积分10
14秒前
自信依瑶完成签到,获得积分10
14秒前
15秒前
金jinjin完成签到 ,获得积分10
15秒前
单薄幻梦发布了新的文献求助10
15秒前
Atlantis30发布了新的文献求助10
15秒前
orixero的应助被Edenn采纳,获得10
16秒前
hyf完成签到,获得积分10
16秒前
许师傅完成签到,获得积分10
16秒前
芳华如梦发布了新的文献求助10
20秒前
20秒前
小冯同学完成签到,获得积分10
21秒前
鸿鹄发布了新的文献求助10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188724
求助须知:如何正确求助?哪些是违规求助? 9576405
关于积分的说明 21847400
捐赠科研通 7786785
什么是DOI,文献DOI怎么找? 3435402
关于科研通互助平台的介绍 2559647
邀请新用户注册赠送积分活动 2482363